Welcome, everyone, and thank you for joining today. My name is Dr. Aoife Egan. I'm a consultant endocrinologist and an assistant professor of medicine at Mayo Clinic, and my co-host is Dr. Jamie Josephson, a consultant pediatric endocrinologist and associate professor of pediatrics at Northwestern. So on the next slide, hopefully you can see how we will be able to connect with members of the interest group outside of the webinar. I'm not able to advance the slides. I'm going to stop sharing for a moment. When you reach out your slides, you see the little arrow in the bottom left corner. Okay, there we go. Great. So, yep, this is what we were looking for, just the information on our members forum where you can connect with members of the interest group at times outside of this current webinar. There is a link in the chat to give you some further information in respect to this. And next, we have a preview of the upcoming live webinars hosted by the ADA, and these are all similar to the one that you're attending now. So hopefully the timing will work and you can join. And again, please visit the link on your screen to register for any of these upcoming webinars. So moving on to today, we have an excellent lineup of speakers from three NIH institutes and the ADA, followed by a question and answer session. And on the next slide, during today's webinar, we would like to hear from you. We encourage you to use the question and answer box in the menu bar to ask questions of the panelists, and we will do our best to address these questions at the end of the presentation. If you would like to comment or discuss the webinar, please use the chat feature, which is also located in the menu bar. And so without further ado, I'd like to give a brief introduction on each of our four speakers. They're all very highly accomplished individuals and we're delighted to have them here for this webinar. So first of all, Dr. Jean Lawrence is a program director in the National Institute for Diabetes Digestive and Kidney Diseases, and she oversees a portfolio of observational studies, secondary data analysis, and natural experiments, as well as studies focused on the risk and prevention of type 2 diabetes after gestational diabetes. Prior to joining NIDDK, she was a senior research scientist at the Department of Research and Evaluation at Kaiser Permanente Southern California, and she has published over 250 peer-reviewed publications and book chapters, many of which fall in the realm of diabetes and pregnancy. Dr. Lawrence has a Bachelor of Arts in Psychology from the University of Michigan, a Master of Social Work from Case Western Reserve University, a Master of Public Health from the University of Pittsburgh, and a Doctor of Science in Maternal and Child Health from the Johns Hopkins Bloomberg School of Public Health. She did postdoctoral training in the Epidemic Intelligence Service at the Centers for Disease Control and Prevention. Next, we have Dr. Candice Price, who represents the National Heart, Lung, and Blood Institute. She is the program director for the Women's Health Initiative Study in the Epidemiology Branch of the Division of Cardiovascular Sciences, and she also manages training grants, including K awards and T32 training programs, which may be of interest to several audience members. Prior to joining NHLBI, Dr. Price was a Building Interdisciplinary Research Careers in Women's Health, often known as BIRCWH, K-12 scholar, and assistant professor at the University of California, Davis. She received her PhD in endocrinology at the University of California, Berkeley, and BA at Wellesley College. Next, we have Dr. Monica Longo, who received her medical degree in 1996 from the Faculty of Medicine at the University of Medina in Italy. And in June 1997, she transitioned to the research team at the University of Texas Medical Branch at Galveston, where she earned her master and PhD degrees in preventive medicine and community health, followed by residency training in obstetrics and gynecology. Her main research interests focus on the maternal physiological adaptations to pregnancy, and in particular, the relationship with cardiovascular and metabolic disease in the mother and offspring. In 2013, Dr. Longo joined the Department of Obstetrics and Gynecology in the University of Texas Health Science Center at Houston as an associate professor, where she established a basic science research lab and pursued fellowship training in maternal fetal medicine. On joining NICHD in 2021, and by focusing on pregnancy, Dr. Longo's ultimate goal is to improve outcomes for mothers and children throughout the lifespan from preconception to later in life. And last but not least, we have Jamie Goodman, who is the managing director, research programs for the American Diabetes Association. And in this role, Jamie is responsible for overseeing the ADA's research funding strategy and grant making infrastructure. In this capacity, she leads the grants management team and the administration of ADA's research portfolio. Previously, Jamie worked at the JDRF International, where she had several roles in both the global access and research departments. Jamie holds a Master of Science degree in non-profit management from the New School, as well as a Bachelor of Arts degree in politics, philosophy and law from Binghamton University. So we'll move over now to get started with our first speaker, Dr. Lawrence. Great, and thank you for that kind introduction and for inviting me to speak at this important webinar on funding diabetes and pregnancy research. I am presenting today on behalf of the NIDDK perspective. Next slide. I will start by talking about the NIDDK strategic plan, followed by our health disparities and health equity research report. I want to let you know where to find this content so that you can review it when developing your research plan. Then I will mention a few notable pregnancy-related initiatives that were funded or co-funded by NIDDK. I'll go over our interests in diabetes and pregnancy space, and I'll tell you who the program contacts are for diabetes and pregnancy at NIDDK. Then I'll conclude with a few things to consider when applying for NIH research funding. Next slide, please. In December 2021, NIDDK published the overarching strategic plan to guide our Institute's priorities for the next four to five years. The plan was developed based on our extensive input from leading researchers across the country, as well as significant public input from patient advocates, organizations, and individuals who responded to the request for information. Next slide, please. The strategic plan outlines four scientific goals, along with cross-cutting topics that are integral to each of these goals. These focus on biological pathways and environmental contributors, clinical studies and trials, dissemination and implementation researchers, and stakeholder engagement. Next slide, please. I am pleased to share that NIDDK's first report on health disparities and health equity research was published in the May of this year, and it is available on NIDDK's website. The image on the left shows the cover of the new report. The recommendations address the social and structural determinants of health across the spectrum of NIDDK's scientific areas. The report provides a cell-to-society perspective in addressing the who, what, where, when, and why equity needs to be at the center of all of our science. It highlights how every researcher, from basic to translational, has a responsibility and role to play in achieving health equity, and that this begins with redefining team science as inclusive of community. Next slide, please. Now let's talk about diabetes and pregnancy research. This includes gestational diabetes and diabetes diagnosed before pregnancy, sometimes referred to as pre-gestational diabetes. Next slide. Here for a bit of background, I'm highlighting a few notable initiatives funded or co-funded by NIDDK focused on diabetes and pregnancy. These are three large observational studies, the HAPO study, the HAPO follow-up study, and the GoMOMS study. GoMOMS is currently in the field recruiting participants. I won't go over all the content on the slide, but there are many publications from both HAPO and HAPO follow-up study that may be of interest, and some of you in the audience have been involved in one or more of these studies. Next slide, please. The Obesity, Pregnancy, and Intrauterine Environment Program at NIDDK supports basic and clinical research to understand the impact of metabolic dysfunction on the intrauterine environment and subsequent metabolic health of both mothers and offsprings, the adverse effects of obesity, gestational diabetes, and type 2 diabetes during pregnancy on mothers and their offspring, and the mechanisms by which the maternal intrauterine environment alters metabolic responses in offspring, which we refer to as imprinting. Next slide. Some specific areas of interest are the relationship between gestational diabetes and subsequent development and prevention of type 2 diabetes in the mother, which is my portfolio, the role of pathophysiological consequences of obesity and or diabetes on the offspring, and the long-term goal is to identify molecular targets that could be therapeutically altered to prevent or ameliorate the increasing incidents and deleterious effects of maternal obesity and type 2 diabetes. Investigator initiative initiated R1s are the bread and butter of what we do. This is where most of the funds are, not in RFAs or cooperative agreements. So I wanted to let folks know, do not assume that since there isn't an RFA or other mechanism that's really specific to your research question that NIDDK is not interested. Call or email us and set up a time to talk about your ideas and your draft aims. Next slide, please. As you can tell by the NIH composition of the panel for this webinar, there are multiple institutes and centers interested in diabetes and pregnancy. NIDDK is usually primary on applications related to the etiology, pathogenesis, natural history, diagnosis, prevention, or treatment of diabetes and its complications, regardless of the age of the population studied. NIDDK is usually primary if the study focuses on unique childhood limited aspects of diabetes. It is not relevant to persons with diabetes of other ages. For gestational diabetes, NIDDK is usually primary on applications on gestational diabetes that focus on the future risk of mothers for developing type 2 diabetes, while NICHD is usually primary for studies of gestational diabetes that focus on the health of the mother during pregnancy or on fetal outcomes. For both gestational diabetes and diabetes, NIDDK and NICHD have shared interests on applications studying the effect of the intrauterine environment on the long-term metabolic health of the offspring. NICHD is usually primary on applications studying the effect of the intrauterine environment on fetal development and infant health. Next slide, please. So, here is a list of program directors in NIDDK that you may consider reaching out to, depending on your topic of interest related to diabetes and pregnancy, and you can find out more about us in the NIDDK staff directory, which is available on the NIDDK website. Next slide, please. Is there one before that? Okay. All right. I will just tell you, we can go to this one, because a little bit out of order. So, what are program officers and reviewers looking for when they're looking at your application? We're looking for compelling research, scientific, significant, and high-impact, exciting ideas, and engaging research. Next slide, please. Hypotheses, alternative proposals, and scientific rigor, a fit to a mechanism, realistic aims and timelines, and I want to caution folks not to be overly ambitious and short on details. Good grant-writing skills so that the content is clear to scientists from a variety of disciplinary backgrounds, a concise, well-written application, trying not to overuse acronyms and abbreviations, and readable tables and figures. Next slide, please. All right. So, I'm going to tell you what's on the slide that I clearly must have deleted. So, I just wanted to tell you a little bit about program directors, because you have three NIH program directors on this webinar. So, we're a resource for applicants. Please contact us early in the process with your draft-specific aims page and biosketch. Early can be four to six months before your deadline. Don't wait until a few weeks before the application is due to try to find the correct person to talk to, because hopefully the input provided will allow you to make modifications or target your application to specific areas of interest to the institutes. If the person you contact isn't the best fit for your interests and aims, they can refer you to the right program director. We do send emails back and forth to each other to find the right person, whether it's within an individual institute or whether it's across institutes. We can help you determine eligibility and responsiveness of proposals to the IC mission and priorities, and then you can reach out to us after your application is reviewed in study section once your summary statement has been released to discuss the next steps. So in conclusion, diabetes and pregnancy research and training is important to NIH. To review NIDDK's strategic plan and pathways to health for all, to learn about the institute's interest, direct your aims and discuss with your colleagues, then reach out to a program director who may be a good fit. If we're not the right person, we can direct you to the person who is. Depending on the content of your application, it may be assigned to NIDDK, NICHD, NHLBI, NIEHS, which is environmental health, or another institute within NIH. And work on scientific topics that are exciting to you. And next slide. And thank you, and we're going to hold questions until all three speakers have talked. All right, good afternoon, or morning, depending on where you are. Okay, so I'm the program director at NHLBI, as was introduced earlier. And next slide, please. I have nothing to disclose. Next slide. Okay, so today I will briefly describe NHLBI's strategic vision, introduce some of our maternal health projects and programs that we are currently funding or co-funding, present some of our current notices of funding opportunities, known as NOFOs, and notices of special interest, talk about taking advantage of our funding opportunities as an early-stage investigator, and describing the differences between an early-stage investigator versus a new investigator. And lastly, introducing some of our program officers that may be useful contacts for research proposals in the area of pregnancy and cardiometabolic health. Next slide. Okay, at NHLBI, our focus is promoting research that cuts across four domains, heart, lung, blood, and sleep. This includes research that expands knowledge of molecular, cellular, and physiological mechanisms of heart, lung, blood, and sleep systems, enhances our understanding of the pathobiology for better prediction, prevention, and treatment of HLBS disorders, advances translational research across the spectrum of basic to clinical to population health, and develop a diverse biomedical workforce to pursue emerging opportunities in HLBS research. Next slide. At NHLBI, maternal health is one of our research priorities, and this is in response to the severe maternal morbidity and mortality disparities we face in the U.S. In 2019, NIH launched what's called the Implementing a Maternal Health and Pregnancy Outcomes Vision for Everyone initiative. This is known as the IMPROVE initiative to support research to reduce preventable maternal mortality, decrease maternal mortality and morbidity, and promote health equity. Now, this is a trans-NIH initiative, meaning that several institutes and centers and offices have participated and co-funded this effort, and this is actually led by the NIACHD, which you'll hear from later, the NIH Office of Research on Women's Health, as well as the National Institute of Nursing Research. Now, recently, the NIH funded two research centers called the IMPROVE Centers of Excellence. These include a data innovation and coordinating hub and an implementation science hub. The implementation science hub will use integrated multilevel approach encompassing structural, social, and biobehavioral research strategies to address the multiple contributing factors that lead to adverse maternal health outcomes and health disparities. So, I do encourage you to visit the IMPROVE website if you're interested in learning more, as they do have funding opportunities that come up relating to maternal health. There are none at the moment that are particularly applicable to pregnancy and diabetes. Next slide. Thank you. But under this initiative, I do want to highlight a couple of other programs in which there is some work being done focused on pregnancy and diabetes. So, NIH also established the IMPROVE-SIT program. This is an NIH effort to test implementation and uptake strategies of interventions aimed at improving maternal health care and health outcomes in community settings. Prior to IMPROVE-SIT, NHLBI, in partnership with the Office of Research on Women's Health, launched the Maternal Health Community Implementation Project, known as MH-SIP, to address maternal health disparities in vulnerable populations. So, you'll see this map here, and I briefly just wanted to demonstrate that some of our…many of our funded sites through MH-SIP and IMPROVE-SIP span across the regions in the U.S. that are most impacted by maternal health mortality and morbidities. Under MH-SIP, we have four awardees, and under three… under IMPROVE-SIP, we have three awardees. So, as it relates to the topic of pregnancy and diabetes, I'd like to point out that one of our awardees, Tulane University in Louisiana, is testing interventions targeting pregnant individuals with diabetes using a modified diabetes prevention program. And in addition, Morehouse School of Medicine, based in Georgia, is testing the implementation of pre-pregnancy counseling for cardiovascular risk factors, including diabetes. Next slide. So, we support several other maternal health cohort studies in pregnant participants. This includes longitudinal studies in which pregnant individuals were followed in the postpartum periods and beyond. In partnership with NICHD, the Nulliparous Pregnancy Outcomes Study Monitoring Mothers-to-be, or NUMOM-to-be for short, is a prospective cohort study in 20 sites across the U.S., and this study evaluated the underlying interrelated mechanisms of several common adverse pregnancy outcomes. In a 20…excuse me, in a 15-year follow-up study, the NUMOM-to-be Heart Health Study was created to evaluate the impact of adverse pregnancy outcomes on future cardiovascular disease, including type 2 diabetes. This study is currently ongoing, and NHLBI co-funded the original cohort to examine the relationship between sleep disorders during pregnancy and adverse pregnancy outcomes. There is also a phase 3 trial called the Continuous Positive Airway Pressure for Sleep Apnea in Pregnancy, which is currently being conducted from this cohort to examine whether treating sleep apnea in pregnancy reduces the risk of adverse cardiometabolic outcomes. Next slide, please. In 2022, NHLBI launched the Early Intervention to Promote Cardiovascular Health of Mothers and Children Study. This is known as ENRICH. This has been funded through a UG3-UH3 grant. The study aims to test the effectiveness of an intervention designed to promote cardiovascular health and address cardiovascular health disparities in both mothers and children from year 0 to 5 years, and as you can see, the study is supported by several institutes' offices as well as HHS partners. Next slide. Lastly, we have the Nurses' Health Study and the Growing Up Today Study, known as GUTS. The Nurses' Health Study is comprised of 3 cohorts spanning 3 generations. There's Nurses' Health 1, 2, and 3. The 3 cohorts capture, because they have spanned generations, they capture pregnancy events and include the offspring, dyads, and triads of the Nurses' Health Study participants. And then the GUTS study is a prospective cohort study of the offspring of the Nurses' Health 2 cohort participants to examine the influence of diet and exercise on weight throughout a person's life. Now, before I talk about our funding opportunities, I want to briefly mention an opportunity for early career investigators. This includes postdocs and junior faculty without major NIH funding, so that would be basically an R01, to apply to participate in our Women's Health Across a Lifespan Cohort Workshop. This workshop is focused on both our Women's Health Initiative Study and our new Mom-to-Be Study that I just mentioned a couple of slides ago. In this workshop, you'll gain hands-on in-person mentoring from the investigators of these two cohorts who are working towards a manuscript for publication within the year. So, if you or someone else may be interested, keep it in mind that the new Mom-to-Be cohort has participants who…they have a lot of pregnant perinatal data and postpartum data, so if this is of interest, please do visit the website or you can email any questions to nhlbicohortstudies at NIH.gov. If you forget that, you can also contact me. Next slide. Okay, I have for you two tables. The top lists are relevant NOFOs and the bottom lists are NOSIs. You may notice we only have one RFA. NHLBI doesn't typically publish a lot of RFAs, similar to NIDDK. Majority of our large funding comes through R01s, so RFAs are quite rare. As it relates to pregnancy and diabetes, one funding mechanism that we support is this RFA listed at the top here. This is for an R21, which is also not common at NHLBI, on understanding chronic conditions understudied among women. This was developed as part of the NIH Strategic Plan for Women's Health Research and is in partnership with the Office of Women's…of Research on Women's Health and other institutes and offices. This RFA supports R21 applications focused on chronic conditions understudied in women and that are disproportionately affected in biomedical research. I will…for interest of time, I'll skip examples that would be relevant, but please visit that RFA announcement if you're interested. The second NOFO here is for R34 proposals, which is essentially pilot clinical trials that are necessary…scientifically necessary in order to design and carry out the subsequent trial of a Phase II, III, or IV clinical trial. These must be primarily intended to test the efficacy, safety, clinical management, and or implementation of the intervention in the prevention and or treatment of a heart, lung, blood, or sleep disorder. Now onto the NOSIs listed in the second table. There are no funds associated with the NOSI. NOSI…you're not applying to a NOSI. You're responding to a NOSI. So, for example, many are linked to parent R01s, and in your application, you would just check the box for B to indicate that you are responding to this specific NOSI. The first one I have listed here aims to advance the IMPROVE initiative and stimulate dissemination and implementation research on innovative approaches built on evidence-based findings from foundational risk research on factors that contribute to maternal morbidity and mortality. The second NOSI here is intended to…a NOSI EB23005 is intended to encourage interest in the small business community to develop various approaches, technologies, and tools to address health issues on maternal morbidity and mortality by achieving a wide array of outcomes. So, again, I encourage you to read that announcement for more information if you're interested in that one. Notice our NOSI DK24001. This is a notice of an upcoming NOSI that is…excuse me…the announcement is a notice of an upcoming NOSI that will be published to solicit applications for research on cardiovascular complications for type 1 diabetes as part of the NIH cardiovascular repository for type 1 diabetes. NOSI MD23002 addresses the etiology of health disparities and health advantages among immigrant populations and supports innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities on health advantages among U.S. immigrant populations. So, if you have a proposal that's related to pregnancy and diabetes in these populations, this could be an appropriate NOSI for that. Now, I should mention that NHLBI only supports 4-year R01 awards. The one…or two exceptions to this rule are we do award 5-year R01s to early-stage investigators or for clinical trials that require patient accrual. Next slide, please. So, if you are an early-stage investigator or ESI, for short, you get to take advantage of higher pay lines. At NHLBI, our current pay line for ESIs is 24. This is in comparison to the non-ESI pay line of 14. So, to qualify for the ESI pay line, you must be both an ESI and a new investigator. So, an ESI, by definition, is a program director or a program director for a definition is a program director or PI who is a principal investigator who has completed their terminal degree or end of postgraduate clinical training, whichever date is later, within the past 10 years and has not previously competed successfully as a PI for a substantial award, in other words, for an R01, whereas a new investigator is a PI who has not previously competed successfully for a substantial research award from NIH, regardless of, even if they're 10 years post-degree. Next slide. If you're unsure if you qualify for an ESI, there's a nice infographic that's provided on the Office of Extramural Research site that is very helpful. The key distinction in regards to the pay line is if you're an ESI, you cannot have already received substantial funding from NIH, and if you're a new investigator, meaning you haven't received an R01 but no longer have ESI status, unfortunately, you do not qualify for the ESI pay line. So, try to take advantage of that while you can. Next slide. And I'll just end by mentioning that if you're interested in submitting an application to NHLBI, keeping in mind that if you submit an application in the area of pregnancy and diabetes, your proposal must include outcomes related to NHLBI's mission areas on heart, lung, blood, or sleep disorders. And I've included some of our colleagues whose portfolios includes pregnancy research, so feel free to reach out with a draft of your specific aims if you have questions about the fit for our institute or responsiveness to specific NOSIs or NOFOs. And if you're interested in an implementation proposal, Dr. Plavikas is a great contact for that. And thank you. Hi, everyone. Like Annie said, good afternoon or good morning. I'm really thankful to my colleagues. They did a great job introducing a lot of things. So I'm going just to try to give you some overview of NICHD. So I'm Monica Longo and they already know that, we already know that. This is my outline. Next one. So as everyone, we have a mission at NICHD and the mission was, the strategic plan was laid out in 2020. And of course, it's a research to understand the human development, improve reproductive health and enhance the lives of children and adolescents for all. And our vision is actually healthy pregnancy, healthy children, healthy and optimal lives. Next. As the other institutes have said, each of us has a team and goal, and we have five teams crossing each other. Understanding team one is understanding the molecular, cellular and structural basis of development. Promoting gynecology, andrology condition and reproductive health. Setting the foundation for healthy pregnancies and lifelong wellness. Improving child and adolescent health and the transition to adulthood. Advancing safe and effective therapeutic and device for pregnant and lactating women, children and people with disability. For which right now there is a task force named PregLag, formed by several different stakeholders. Next. So some of the overview of the NICHD research on diabetes. This is like a kind of a tire which shows, and we have a large portfolio on diabetes to conduct on many aspects from not only gestational diabetes. I mean, it's all related to pregnancy, but there's the mechanism, the obesity role in chronic disease, and also the diabetes management in children and the long term in women as. As said by others, we work closely with NIDDK, which as you know, is the main institute involved in diabetes. But of course, as you said, as you heard from my colleague, we work with NHLBI and other institutes to understand the mechanism and treatment for diabetes and its effect on long term health. Next. These are some institute specific branch activity. We have the pediatric growth and nutrition branch, and I didn't have a program officer specific slides at the end. So these will be Dr. Weiner is the chief of this branch and they're working on developing method for predicting diabetes in childhood. Technique of immunomodulation to prevent dysregulation of pancreatic beta cell. Method to stratify risk of type 1 diabetes. We have also the population dynamic branch led by Dr. Clark, which they do research and training in demographic reproductive health and population health, also related in the diabetes contest. And the branch where I am is the pregnancy and perinatology branch led by Dr. Shakthura, which we do research mostly focus on high risk pregnancy from various condition as hypertension, preeclampsia, and of course, diabetes and gestational diabetes and the long term maternal and neonatal outcome. Next. Now, I'm going to give you an overview of one of the pillars that are in our branch that are called the clinical network is a cooperative agreement. It's a little bit different type of agreement of the classical R01, but I wanted to talk to you about that because now it is open to outside investigators. So you don't have to have the infrastructure belong to the network, you can apply to it. Next. Next. One of the one you probably have more interest or came up you might come across was the Maternal Fetal Medicine Union Network, which was established in 1996 to conduct clinical trial in maternal fetal medicine obstetrics to conduct definitive rigorous and reproducible inside clinical and observational trial in pregnant and lactating women providing evidence to clinical practice. Next. Now, this has just recompeted this year, and we have now 14 centers which are spanning across. Unfortunately, we don't have as many in the West that we would like, but that's why it's important that you know about this mechanism because outside investigators can apply. You don't need to have been one of these centers. These centers have shown to have the infrastructure to conduct the clinical trial, but idea and proposal can come from outside investigators also. This is an important network which had led to more than 300 500 publication that 25% of impact and change our guideline of pregnancy care. Next. This is one of the study that was specifically done in diabetes from this network was a multi center randomized trial. Trial is actually come from long time ago is almost seven years but was the one that changed our way to treat gestational diabetes, it was randomly assigned of women with the GDM to treatment and not treatment and older did not show not seem to not reduce the frequency of composite outcome as far as stillbirth or perinatal death, or other neonatal complication did reduce the risk of fetal overgrowth, shoulder distortion, cesarean delivery and hypertensive disorder. Next. And these became actually one of our practice bulletin in our, I'm sorry before. Thanks. As far as the American Central of setting and gynecology, where we follow this guideline and now we are very aggressive in treating gestational diabetes to prevent those complication. Next. This is the maternal the global network. This could be one of those you might not know a lot. It is started in 2001 is a public private partnership between an ICHD and the Bill Melinda Gates Foundation. It is also the purpose of improving the health of mother and children to this partnership. Next. And it's found across the world. From Congo, Zambia, Guatemala, Bangladesh, India, Pakistan, and this form by OBGYN PhD and I think this is another great opportunity for you to think in this direction. Next. We have the neonatal research network, which is another big pillar of an ICHD also formed in 1986 is also U01 collaborative network of neonatal intensive care unit across the United States with the goal to improve the health care and outcome for newborn, even up to five to seven, seven years they've been follow up. Next. These also have been recompeted recently. These are the 16 center and each of them has their own DCC. They publish also more than 500 350 paper. And again, six more than around 30% have impact our guideline on neonatal management. The reason I next. The reason I wanted to bring to your attention those three network was because, again, like I said, these now is an open process before it was very limited. If you were part of one of the Institute that had the infrastructure now to the PR 23027 as an outside investigator, you can reach out to some of the people in those network and discuss maybe your aim and evaluate if your idea could be feasible with those infrastructure. Well, is that population is applicable to your study and you could apply there is a several step, but you can send a letter, you will send a letter of inquiry to an ICHD, we will look at and see if it's actually can leverage one of these natural with your idea, your concept, you can be a recruiting Institute or not, if you don't have the capability of recruiting. And after there is the other step process, which I'm not going into the detail, but you are welcome to reach me how to submit the concept and ultimately will go to a study section for a peer review. Next. One thing I didn't. One thing I didn't. It require all the different lecture but I just again like my colleague, talk to you about in their Institute, we also have dash which is the data and specimen hub is a centralized resources for researchers to store the identified data access data. You don't need to reach biospacement for secondary research to apply for grant, you don't need an account to browse like you do PubMed to see if there could be some data set associated with biospacement that you could leverage with your, in your Institute, you will need only an account, if you plan to submit. Of course, the data are not cost associate, but the date this by biospacement there is a cost, then you will enquiry with an ICHD just because it has to be a shipment process associated with it. Next, I will go very quick through this because my colleague did a great job but as you can see there is one NIH but there are 27 different Institute each of us as kind of a mission budget activity way to kind of a little bit different some of us work more on one sector some on the other, as far as in their mechanism. And so it's important that you reach out to us as soon as you start planning or talking to more than one, we can get in a different in a call together. Next, and to try to answer as many questions as we can. As I said, it's very important and you try to talk to you find your mentor colleague, and look through some of the mechanism web mechanism we have like NIH reporter or matchmaker to find a program office that could fit better. The IC that could fit better your strategies, your funding idea where you're looking, what are you looking. Next. And overall, like my colleague said, just learn how the process goes may make early contact with us. We are very open to talk to you and like I said getting a call together be innovative right now. Every institute is look for innovation, and it doesn't have to be could be a way you're designing your plan statistical innovation are becoming very important technology. Be creative and don't get discouraged and reach out to us. Next. Thank you. I didn't put my mail but I forgot I'm sorry but you can find me, and I see HD and be happy to talk to all of you. Anytime. Thank you. Hi, everyone. I'm Jamie go and I'm the managing director of research programs for the American Diabetes Association. In the interest of time saying that we're running out, I may skip over some aspects. However, if you have any questions, please feel free to hear myself or great questions. Next slide. So, um, yeah, we might as well go to this one I think we all are acquainted with his mission and its dedication to research over the past, I would say 70 years since the ADA was created. For the research programs team, we're really focused on supporting early stage research with the high potential to benefit people with diabetes, getting more and more people into the diabetes field and giving them funding to stay in the field. See someone have brain drain recently of people leaving for more recruitive areas of research. And what we wanna do is try to bring more and more people into the door so we can get the best of the best research into the hands of those that we get. Currently, we have a portfolio and actually kind of grew overnight because we just funded a bunch of grants. So I would say it's actually going to be around 180 active research projects at 80 leading research institutions in the United States in 2023. And so if you go to the next slide. So anytime you wanna know what's going on, what ADA has to offer in terms of funding, please feel free to go to our website and just put the link into the chat. This is where you can find up-to-date information on the R phase and other funding opportunities that are offered throughout the year. And it's also where you could find information, FAQs, you name it on what ADA expects our grantees to do. Next slide. All right, so we have targeted research funding opportunities. So once a year, usually in September, we will launch three different R phase that are on various topics that are open to pretty much all aspects of diabetes and all subject matters. However, it just needs to align with the topic area per se. And it really is our way of being more strategic with how we fund and staying up to date with what we're doing. And staying up to date with what the field is really saying that they need in terms of research and where the gaps and challenges are. So we offer three different types of funding mechanisms, which are junior faculty awards, innovative clinical and translational science award, and innovative basic science awards. And they all different, they range in different areas of eligibility and cost per year. They usually are up to three years for all of these mechanisms. In 2024, we will be launching our brand new topics. Our topic areas are usually for two cycles. So the topic areas will be released in September, 2023. That is going to be the last round. One of those are women's health RFA, which unfortunately the LOIs for that, go to the next slide in a second. Actually, we could probably go now to speed it up. So unfortunately, the LOIs for this RFA were submitted on November 30th. The timing of this webinar and that weren't the greatest. However, one of the aims of that RFA was focusing on pregnancy and to improve screening and pregnancy outcomes in women with diabetes and reduce the risk of subsequent type twos and those with achieved that. So with these targeted opportunities, we offer them pretty broad in scope. So even if an RFA doesn't exactly call out pregnancy as an aim or an area of interest, it does not mean it's not eligible in terms of subject matter to apply. It just needs to relate to the topic per se. We also have offered this round a mental and behavioral health RFA. So obviously, it may not call pregnancy out there, but I'm sure we all can relate that there are aspects of pregnancy that would be very applicable. So we are getting that review underway. We're very excited about it. However, this will be the last round offered for this topic area. New ones are currently being discussed. We'll probably be announcing the new targeted topics that will be launched in September, 2024. But it will be announced in the spring, definitely prior to ADA Scientific Sessions, which I hope you all join us in June in Orlando. So stay tuned for more information. I wish I could tell you more now, but we're pretty excited of what's to come. Next slide. So another area that we offer, this is now an annual call. We used to have postdoctoral fellowships in our targeted RFA, but what we wanted to do instead is pull them out and offer it annually, really to help engage more people in the field and applying for postdocs and getting people the funding that they need to stay in diabetes, especially those who are girls in their 20s. Postdoctoral fellowships are open to all aspects and topic areas of diabetes. So any pregnancy-related area, you're welcome to apply. Obviously, we have a postdoctoral department on this. You can find more information on our website. We will be launching the next cycle- Oh, Jamie, we're having a hard time hearing you. How about now? Am I good? Yes. So we will be launching the next cycle of this in April, 2024. It'll have a pretty extensive application timeframe. So, you know, fellows are all over the place. We want to give them enough time to put an application together and work with their mentors. So this was the first year we offered it, and now it's going forward. It's so successful, we're going to offer it annually. And then our other annual call that we have offered, and it's the most prestigious award that the EDJ has, is the Pathway to Stop Diabetes. So this is really investing in early-career investigators. It was launched 10 years ago to really expand the pipeline of getting people into the field. So, you know, the Pathway to Stop Diabetes has a revolutionary goal. It's to find scientists at the peak of creativity and provide them with flexibility and resources they need on the road to breakthrough discoveries. And it gives researchers at a critical stages in their career, not only the resources and the protected time to pursue the research, but the freedom and financial flexibility. And what we mean by that is, you know, let's say you start on one topic area, let's say hypoglycemia, and, you know, in the course of your research, you're like, I found other breakthroughs in XYZ areas. You are allowed to shift. And it really gives people the freedom that not, you know, generally speaking, other kinds of awards may not offer in terms of change of scope. These awards can be anywhere between five to seven years, up to $1.6 million in that timeframe, up to 325K per year. Typically fund up to two awards per year, and can have one person from the institution apply. However, you know, fundraising goes well. We can hopefully increase the number of those awardees per year. So let's all hope for that. And we will be launching the next cycle in March, 2024. And generally we give applicants until the beginning of the summer to submit. So very exciting to come. Please take a look at it. And obviously any aspects of pregnancy are welcome to be for people to apply to Pathway. We're actually currently funding a Pathway awardee that is focusing on gestational diabetes pregnancy. So it has been funded. If you go to the next slide. Jamie, I'm gonna ask you just to wrap up because we do wanna have like a few minutes for last minute questions. Yeah, so essentially if you have a lot more information or questions, I guess I could wrap up here. Feel free to reach out to us at grantquestions.diabetes.org. And I'll hand it back over to you guys if you have a question. Thank you so much, Jamie. Sorry to cut you off. But we're running out of time. I think it was really, thank you all to our speakers for joining us and providing an overview at each of their funding centers. We had asked for questions to be submitted upon registering so that we could try to address them. I hope that most of your questions were addressed. One question that I just wanted to bring up was, and I know Jean kind of alluded to this, but I think it would be a good idea to reiterate. When in the grant writing process is it most appropriate to engage with a program officer just to make sure, okay, are you submitting your grant to the right institute? And are you kind of meeting what's needed to have a successful proposal submitted? So I don't know if somebody wants to take that question. I'll start. I would say part of that depends on what stage you are. If this is your first R01, for example, start as early as possible, like nine months at least ahead of time, because it does take some time to get that proposal in good shape to submit it. And otherwise, if you're someone that's at least gone through the process before, I'd advise no less than two months in advance with a fairly decent draft of your aims. And I just want to point out before we have to wrap up soon that this recording is going to be available and in a few weeks, and that there's a bunch of different links that our speakers have put into the chat with the different websites. And then another question, because I noticed during these talks that we talked briefly about like pre-gestational diabetes, but are there funds specifically going towards research in treatment or type two diabetes in pregnancy? So do you want me to take some of it, Gina? Sure, sure. Just very quick. I mean, from our standpoint, I mean, the funding are not, right? We have a certain amount of fund and funding are going that direction, but of course it depends on the grant application, the scoring, it's very competitive, but I have several funding, sorry, I have like in treatment, like even just nutritional treatment, I know it all, or exercise. So I have several in my portfolio. So there are funding, but not like you can find it under one voice, right? Correct. So some end up in my portfolio as well. So it really just depends. That's why it's really good to contact us early because we can kind of try to sort out. I think the question that was asked had a variety of, had an exposure and a variety of outcomes, the one that was asked in the chat. And so what we would try to do is sit down and figure out which institute mostly has those outcomes. And that actually leads me to a comment that you don't wanna put every outcome in one application because while you may think this is really gonna wow the reviewers, we ahead of time actually will try to help you sort out the outcomes so that they're mostly clustered under one institute's interest, which doesn't mean you can't submit different applications looking at different outcomes as long as they're not almost completely repetitive. But if we can help you sort it out ahead of time, we can then kind of facilitate that process with you. But if there's one outcome from NHLBI and one from NICHD and one NIDDK is interested in, oh, maybe environmental health, it gets really difficult to figure out where that application is gonna live. It will go through peer review, but then once we have to figure out once it's scored, which institute is gonna be primary and different institutes have different paylines. So these are all kind of thing, but whether one payline's better, but that institute may cut in a different way unrelated to the payline. So I just wanted to put that out there that early is better to help you guys sort out your research questions and institutes. Thank you so much, Jean. I wish we could stay on longer because I'm sure there's a lot more questions, but we're being told that we need to wrap up. So again, I really thank each of you for presenting to us. And this was, I thought, a great webinar, especially for individuals who are early career and just starting to explore funding opportunities in the area of diabetes and pregnancy. So thank you. Well, thank you for having us. We leave? Bye everyone. Bye, thank you.

American Diabetes Association

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases

National Heart, Lung, and Blood Institute

Eunice Kennedy Shriver National Institute of Child Health and Human Development

webinar

funding opportunities

diabetes and pregnancy research

research priorities